B. Riley Comments on CymaBay Therapeutics Inc’s FY2018 Earnings (CBAY)

Share on StockTwits

CymaBay Therapeutics Inc (NASDAQ:CBAY) – Equities researchers at B. Riley issued their FY2018 earnings per share (EPS) estimates for shares of CymaBay Therapeutics in a note issued to investors on Tuesday, February 5th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will earn ($1.27) per share for the year. B. Riley currently has a “Hold” rating and a $9.00 target price on the stock. B. Riley also issued estimates for CymaBay Therapeutics’ Q4 2018 earnings at ($0.36) EPS, Q1 2019 earnings at ($0.41) EPS, Q2 2019 earnings at ($0.46) EPS, Q3 2019 earnings at ($0.51) EPS, Q4 2019 earnings at ($0.56) EPS, FY2019 earnings at ($1.95) EPS, FY2020 earnings at ($2.26) EPS, FY2021 earnings at ($2.93) EPS, FY2022 earnings at ($1.76) EPS and FY2023 earnings at ($1.99) EPS.

Several other research firms have also recently commented on CBAY. Zacks Investment Research cut CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 21st. Oppenheimer set a $18.00 price target on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Sunday, December 9th. BidaskClub upgraded CymaBay Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, January 1st. ValuEngine cut CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of CymaBay Therapeutics in a research note on Friday, November 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. CymaBay Therapeutics has a consensus rating of “Buy” and a consensus target price of $18.89.

CymaBay Therapeutics stock opened at $9.27 on Friday. CymaBay Therapeutics has a 12 month low of $6.31 and a 12 month high of $15.59. The company has a market cap of $551.01 million, a PE ratio of -11.73 and a beta of 1.72.

In other CymaBay Therapeutics news, CEO Sujal Shah acquired 10,000 shares of the business’s stock in a transaction on Friday, December 21st. The stock was purchased at an average price of $6.54 per share, for a total transaction of $65,400.00. Following the completion of the transaction, the chief executive officer now owns 110,000 shares of the company’s stock, valued at approximately $719,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kurt Von Emster sold 142,381 shares of the stock in a transaction on Tuesday, December 18th. The stock was sold at an average price of $7.89, for a total value of $1,123,386.09. Following the completion of the transaction, the director now owns 90,000 shares of the company’s stock, valued at approximately $710,100. The disclosure for this sale can be found here. Corporate insiders own 4.50% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in CBAY. BlackRock Inc. raised its position in CymaBay Therapeutics by 246.8% in the second quarter. BlackRock Inc. now owns 4,054,285 shares of the biopharmaceutical company’s stock worth $54,410,000 after acquiring an additional 2,885,082 shares in the last quarter. Eagle Asset Management Inc. raised its position in CymaBay Therapeutics by 37.9% in the third quarter. Eagle Asset Management Inc. now owns 2,844,766 shares of the biopharmaceutical company’s stock worth $31,520,000 after acquiring an additional 781,700 shares in the last quarter. Carillon Tower Advisers Inc. raised its position in CymaBay Therapeutics by 42.5% in the third quarter. Carillon Tower Advisers Inc. now owns 2,061,772 shares of the biopharmaceutical company’s stock worth $22,844,000 after acquiring an additional 614,502 shares in the last quarter. Northern Trust Corp raised its position in CymaBay Therapeutics by 496.6% in the second quarter. Northern Trust Corp now owns 679,176 shares of the biopharmaceutical company’s stock worth $9,115,000 after acquiring an additional 565,327 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. raised its position in CymaBay Therapeutics by 103.8% in the third quarter. Candriam Luxembourg S.C.A. now owns 958,000 shares of the biopharmaceutical company’s stock worth $10,615,000 after acquiring an additional 488,000 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Read More: What are the Different Types of Leveraged Buyouts?

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply